Blinding a CYCLOPS
Targeted therapies are changing cancer treatment. Designed
to wield laser-like precision, they focus on overactive proteins produced by
mutated genes, destroying cancer cells but sparing normal cells. Most of the
cancer drugs created in the last decade follow that model, exploiting knowledge
of genetic mutations to stop cancer’s progression rather than aiming a
fusillade of chemotherapy agents against all fast-growing cells, normal or
cancerous.